Cerity Partners’s Aardvark Therapeutics AARD Stock Holding History

Cerity Partners’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$62K	Buy	+10,771	New	+$50.3K	﹤0.01%	3278

Other funds holding AARD

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Cerity Partners's AARD Position: Q2 2026 in Review

Cerity Partners opened a new position in Aardvark Therapeutics (AARD) in Q2 2026: 10,771 shares worth $62K. The stake represents ﹤0.01% of the portfolio and ranks #3278 among its holdings.

72 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

Cerity Partners held 10,771 shares of Aardvark Therapeutics worth $62K as of Q2 2026.
Aardvark Therapeutics was a new Cerity Partners position in Q2 2026.
Aardvark Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3278 holding.
72 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.